Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Erlotinib in Advanced Gallbladder Carcinoma or Cholangiocarcinoma
NCT01093222Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and erlotinib in gallbladder carcinoma and cholangiocarcinoma (CCA), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival up to 3 years. Started Apr 2010; status: completed.
02
Drugs
sorafeniberlotinib
03
Conditions
gallbladder carcinomacholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT01093222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093222.